The efficacy and safety of lenvatinib in the treatment of solid tumors: an up-to-date meta-analysis

被引：1

作者：

Xie, Wen jie ^{[2
]}

Zhang, Shuai ^{[2
]}

Su, Lei ^{[1
]}

Li, Yan hong ^{[1
]}

Zhang, Xi ^{[1
]}

Ran, Yu ge ^{[1
]}

机构：

[1] Hebei Univ, Affiliated Hosp, Dept Radiotherapy, Baoding 071000, Peoples R China

[2] Baoding First Cent Hosp, Dept Gen Surg, Baoding 071000, Peoples R China

来源：

FUTURE ONCOLOGY | 2021年 / 17卷 / 06期

关键词：

cancer patients; efficacy; lenvatinib; meta-analysis; safety; ENDOTHELIAL GROWTH-FACTOR; UNRESECTABLE HEPATOCELLULAR-CARCINOMA; TYROSINE KINASE INHIBITOR; PHASE-II; OPEN-LABEL; CANCER; COMBINATION; SORAFENIB; THERAPY; TRIAL;

D O I：

10.2217/fon-2020-0327

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Aim: We performed an updated meta-analysis to evaluate the efficacy and safety of lenvatinib in cancer patients. Materials & methods: Databases were searched to identify relevant trials. Data were extracted to evaluate overall survival, progression-free survival, overall response rate and grade >= 3 adverse events. Results: The pooled analysis demonstrated that lenvatinib significantly improved progression-free survival (hazard ratio: 0.43; 95% CI: 0.23-0.80; p = 0.008), overall survival (hazard ratio: 0.85; 95% CI: 0.75-0.97; p = 0.013) and overall response rate (relative risk: 6.89; 95% CI: 2.22-21.36; p = 0.001) compared with control therapy. However, the use of lenvatinib can increase the risk of severe infection. Conclusion: Lenvatinib-containing regimens are associated with better progression-free survival, overall survival and overall response rate, but can induce severe infection.

引用

页码：745 / 754

页数：10

共 36 条

[1] A Phase 2 Trial of Lenvatinib (E7080) in Advanced, Progressive, Radioiodine-Refractory, Differentiated Thyroid Cancer: A Clinical Outcomes and Biomarker Assessment [J].

Cabanillas, Maria E. ;

Schlumberger, Martin ;

Jarzab, Barbara ;

Martins, Renato G. ;

Pacini, Furio ;

Robinson, Bruce ;

McCaffrey, Judith C. ;

Shah, Manisha H. ;

Bodenner, Donald L. ;

Topliss, Duncan ;

Andresen, Corina ;

O'Brien, James P. ;

Ren, Min ;

Funahashi, Yasuhiro ;

Allison, Roger ;

Elisei, Rossella ;

Newbold, Kate ;

Licitra, Lisa F. ;

Sherman, Steven I. ;

Ball, Douglas W. .

CANCER, 2015, 121 (16) :2749-2756

[2] Final results of the TALENT trial (GETNE1509): a prospective multicohort phase II study of lenvatinib in patients (pts) with G1/G2 advanced pancreatic (panNETs) and gastrointestinal (giNETs) neuroendocrine tumors (NETs). [J].

Capdevila, Jaume ;

Fazio, Nicola ;

Lopez, Carlos Lopez ;

Teule, Alex ;

Valle, Juan W. ;

Tafuto, Salvatore ;

Custodio, Ana B. ;

Reed, Nicholas ;

Raderer, Markus ;

Grande, Enrique ;

Garcia-Carbonero, Rocio ;

Jimenez-Fonseca, Paula ;

Alonso, Vicente ;

Antonuzzo, Lorenzo ;

Spallanzani, Andrea ;

Berruti, Alfredo ;

Sevilla, Isabel ;

Munoa, Adelaida La Casta ;

Hernando-Cubero, Jorge ;

Ibrahim, Toni .

JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)

[3] METAANALYSIS IN CLINICAL-TRIALS [J].

DERSIMONIAN, R ;

LAIRD, N .

CONTROLLED CLINICAL TRIALS, 1986, 7 (03) :177-188

[4] Renal cell cancer: overview of the current therapeutic landscape [J].

Erman, Mustafa ;

Benekli, Mustafa ;

Basaran, Mert ;

Bavbek, Sevil ;

Buyukberber, Suleyman ;

Coskun, Ugur ;

Demir, Gokhan ;

Karabulut, Bulent ;

Oksuzoglu, Berna ;

Ozkan, Metin ;

Sevinc, Alper ;

Yalcin, Suayib .

EXPERT REVIEW OF ANTICANCER THERAPY, 2016, 16 (09) :955-968

[5] Role of Raf kinase in cancer: Therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway [J].

Gollob, Jared A. ;

Wilhelm, Scott ;

Carter, Chris ;

Kelley, Susan L. .

SEMINARS IN ONCOLOGY, 2006, 33 (04) :392-406

[6] Lenvatinib plus everolimus or pembrolizumab versus sunitinib in advanced renal cell carcinoma: study design and rationale [J].

Grunwald, Viktor ;

Powles, Thomas ;

Choueiri, Toni K. ;

Hutson, Thomas E. ;

Porta, Camillo ;

Eto, Masatoshi ;

Sternberg, Cora N. ;

Rha, Sun Young ;

He, Cixin S. ;

Dutcus, Corina E. ;

Smith, Alan ;

Dutta, Lea ;

Mody, Kalgi ;

Motzer, Robert J. .

FUTURE ONCOLOGY, 2019, 15 (09) :929-941

[7] Evaluation of Targeted Agents for Advanced and Unresectable Hepatocellular Carcinoma: A Network Meta-Analysis [J].

Guo, Tao ;

Liu, Pengpeng ;

Yang, Jian ;

Wu, Ping ;

Chen, Baiyang ;

Liu, Zhisu ;

Li, Zhen .

JOURNAL OF CANCER, 2019, 10 (19) :4671-4678

[8] A phase 2 study of lenvatinib in patients with RET fusion-positive lung adenocarcinoma [J].

Hida, Toyoaki ;

Velcheti, Vamsidhar ;

Reckamp, Karen L. ;

Nokihara, Hiroshi ;

Sachdev, Pallavi ;

Kubota, Tomoki ;

Nakada, Takuya ;

Dutcus, Corina E. ;

Ren, Min ;

Tamura, Tomohide .

LUNG CANCER, 2019, 138 :124-130

[9] Measuring inconsistency in meta-analyses [J].

Higgins, JPT ;

Thompson, SG ;

Deeks, JJ ;

Altman, DG .

BMJ-BRITISH MEDICAL JOURNAL, 2003, 327 (7414) :557-560

[10] Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma [J].

Ikeda, Kenji ;

Kudo, Masatoshi ;

Kawazoe, Seiji ;

Osaki, Yukio ;

Ikeda, Masafumi ;

Okusaka, Takuji ;

Tamai, Toshiyuki ;

Suzuki, Takuya ;

Hisai, Takashi ;

Hayato, Seiichi ;

Okita, Kiwamu ;

Kumada, Hiromitsu .

JOURNAL OF GASTROENTEROLOGY, 2017, 52 (04) :512-519

← 1 2 3 4 →